TCM
TCG Crossover Management Portfolio holdings
AUM
$876M
This Quarter Return
+53.95%
1 Year Return
+23.66%
3 Year Return
+996.72%
5 Year Return
–
10 Year Return
–
AUM
$902M
AUM Growth
+$902M
(+33%)
Cap. Flow
+$65.2M
Cap. Flow
% of AUM
7.24%
Top 10 Holdings %
Top 10 Hldgs %
61.32%
Holding
31
New
5
Increased
2
Reduced
1
Closed
2
Top Buys
| 1 |
Tourmaline Bio
TRML
|
$26.4M |
| 2 |
Structure Therapeutics
GPCR
|
$24.7M |
| 3 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
$14.8M |
| 4 |
VistaGen Therapeutics
VTGN
|
$13.8M |
| 5 |
ABVX
Abivax
ABVX
|
$11.8M |
Top Sells
| 1 |
Taysha Gene Therapies
TSHA
|
$14.5M |
| 2 |
Immunovant
IMVT
|
$12.9M |
| 3 |
Merus
MRUS
|
$7.07M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
C4 Therapeutics
CCCC
$185M
| $7.21M | 0.8% |
1,276,574
| – | – |
|
|
27
Taysha Gene Therapies
TSHA
$797M
| $5.16M | 0.57% |
2,912,861
-8,198,250
| -74% | -$14.5M |
|
28
Ventyx Biosciences
VTYX
$171M
| $2.01M | 0.22% |
815,724
| – | – |
|
29
Kodiak Sciences
KOD
$478M
| $815K | 0.09% |
+267,941
| New | +$815K |
|
|
30
Immunovant
IMVT
$2.56B
| – | – |
-334,853
| Closed | -$12.9M |
|
|
31
Merus
MRUS
$4.98B
| – | – |
-300,000
| Closed | -$7.07M |
|